-
Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation
2026-08-23
Chavali and colleagues developed a chemically defined differentiation strategy that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells from induced pluripotent stem cells with high purity and improved reproducibility. The workflow provides a practical foundation for glaucoma modeling, RGC biology, and cell-replacement research while highlighting the importance of standardized lineage enrichment and validation.
-
BRD4770: G9a Histone Methyltransferase Inhibitor
2026-08-22
BRD4770 is a G9a histone methyltransferase inhibitor that lowers intracellular H3K9 methylation and produces senescence-associated phenotypes in PANC-1 cells. Its reported biochemical IC50 is 6.3 μM, while breast-cancer evidence supports a related G9a-centered pathway but does not directly validate BRD4770.
-
CA-074 Me: Cathepsin B Inhibitor Guide
2026-08-22
CA-074 Me is a membrane-permeable cathepsin B inhibitor with a reported biochemical IC50 of 36.3 nM. Its use in lysosomal enzyme inhibition, apoptosis assay design, necroptosis studies, and inflammation research requires attention to cathepsin L cross-inhibition under reducing conditions and solvent handling.
-
GRE Suppresses Melanogenesis via CREB/MITF
2026-08-21
The reference study shows that combining glabridin, resveratrol, and ellagic acid produces coordinated anti-melanogenic, antioxidant, and anti-inflammatory activity in cell-based assays. Its most important mechanistic finding is suppression of CREB phosphorylation and MITF-associated pigmentation signaling, providing a testable framework for pigmentation regulation research while leaving in vivo efficacy and combination synergy unresolved.
-
In Vitro Cancer Drug Responses: Beyond Relative Viability
2026-08-20
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework that separates growth inhibition from cell killing, showing that drugs can influence both processes with different magnitudes and timing, with important consequences for assay design and interpretation.
-
Sodium Ascorbate for ROS Cancer Research
2026-08-20
Sodium Ascorbate enables solvent-controlled studies of intracellular ROS, tumor-cell injury, proliferation, and motility in cancer models. This workflow also shows how to keep ROS experiments distinct from, yet complementary to, emerging GPNMB-based immunotherapy biomarker research.
-
GM 6001: Designing Causal MMP Assays
2026-08-19
GM 6001 (Galardin) enables broad-spectrum MMP inhibition for mechanistic ECM, signaling, and cancer research. This article explains how to use it as a causal assay control while interpreting matrix effects alongside lysosomal membrane permeability and cell-death findings.
-
Q-VD-OPh: Pan-Caspase Inhibitor Workflow
2026-08-19
Use Q-VD-OPh to separate apoptosome assembly from downstream caspase execution in live-cell apoptosis experiments. Its cell and brain permeability also supports post-cryopreservation recovery studies and carefully controlled neurodegeneration models.
-
Mitoguardin-2 Preserves Mitochondrial Lipid Homeostasis
2026-08-18
Hong and colleagues identify mitoguardin-2 (MIGA2) as a lipid transfer protein at mitochondria–ER and mitochondria–lipid droplet contacts. Structural, mass spectrometric, in vitro transport, and cellular evidence connects a hydrophobic lipid-binding cavity in MIGA2 to preservation of mitochondrial morphology and lipid droplet formation.
-
Sulfo-Cy5 NHS Ester Workflow Guide
2026-08-18
Sulfo-Cy5 NHS ester enables far-red labeling of amine-containing proteins and ligands in aqueous workflows, making it useful for solvent-sensitive samples and cellular uptake studies. This guide connects conjugation chemistry with VLA-4 imaging, dendritic-cell assays, and practical troubleshooting.
-
a-MSH, Amide: Assay Design Beyond Melanogenesis
2026-08-17
Explore how a-MSH, amide functions as a defined melanocortin perturbation tool for pigmentation, receptor pharmacology, and inflammation research. This article emphasizes assay interpretation, peptide handling, and the practical significance of separating α-MSH-driven stimulation from anti-melanogenic intervention.
-
Viability Versus Cell Death in Cancer Drug Response
2026-08-17
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an anticancer response. This framework helps researchers design time-resolved assays and interpret apoptosis-focused compounds without mistaking reduced metabolic or proliferative activity for cytotoxicity.
-
QNZ (EVP4593): From NF-κB Biology to Translation
2026-08-16
A translational framework for using QNZ (EVP4593) to connect NF-κB pathway modulation with inflammation and Huntington’s disease research while protecting assay interpretation, compound handling, and strategic decision-making.
-
In Vitro Assays for Growth Arrest and Cell Death
2026-08-15
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different components of anticancer drug response. The work indicates that proliferation arrest and cell death often occur together but differ in magnitude and timing, supporting paired, time-resolved assay strategies for more reliable interpretation.
-
Lipo3K Transfection Reagent: Practical Workflow
2026-08-14
Lipo3K Transfection Reagent supports DNA, siRNA, mRNA, plasmid co-transfection, and workflows involving difficult-to-transfect cells while minimizing avoidable cell stress. This guide translates a pH-responsive antisense oligonucleotide study into practical delivery, assay-design, and troubleshooting decisions.